Ivonescimab plus chemotherapy “demonstrated strongly positive results” as a first-line treatment for advanced squamous NSCLC.
Immunotherapy in Non-Small Cell Lung Cancer
Advertisement
A recent study may provide a "clearer, more individualized" understanding of progression risk after discontinuation.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
The study included patients with advanced NSCLC with PD-L1 expression of at least 50% and no EGFR, ALK, or ROS abberations.
Investigators of a phase 2 study uncovered a biomarker that may be associated with major pathologic response in this setting.
The study investigators concluded that ivonescimab “might represent another treatment option in the first-line setting."
Researchers evaluated if there was a link between pretreatment systemic immune inflammation index levels and outcomes.
The therapy is currently under evaluation in phase 1 and phase 2 trials.
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.